Generation and characterization of antibodies specific for caspase-cleaved neo-epitopes: a novel approach

被引:17
作者
Ai, X. [1 ]
Butts, B. [1 ]
Vora, K. [2 ]
Li, W. [1 ]
Tache-Talmadge, C. [1 ]
Fridman, A. [3 ]
Mehmet, H. [1 ]
机构
[1] Merck Res Labs, Apoptosis Biomarkers, Rahway, NJ 07065 USA
[2] Merck Res Labs, Immunol Franchise, Rahway, NJ 07065 USA
[3] Merck Res Labs, Appl Comp Sci & Math, Rahway, NJ 07065 USA
关键词
Biomarker; apoptosis; neo-epitope antibodies; MEDIATED PROTEOLYSIS; CONJUGATE VACCINES; APOPTOSIS PATHWAYS; CROSS-REACT; BIOMARKERS; PROTEIN; SITES;
D O I
10.1038/cddis.2011.91
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Apoptosis research has been significantly aided by the generation of antibodies against caspase-cleaved peptide neo-epitopes. However, most of these antibodies recognize the N-terminal fragment and are specific for the protein in question. The aim of this project was to create antibodies, which could identify caspase-cleaved proteins without a priori knowledge of the cleavage sites or even the proteins themselves. We hypothesized that many caspase-cleavage products might have a common antigenic shape, given that they must all fit into the same active site of caspases. Rabbits were immunized with the eight most prevalent exposed C-terminal tetrapeptide sequences following caspase cleavage. After purification of the antibodies we demonstrated (1) their specificity for exposed C-terminal (but not internal) peptides, (2) their ability to detect known caspase-cleaved proteins from apoptotic cell lysates or supernatants from apoptotic cell culture and (3) their ability to detect a caspase-cleaved protein whose tetrapeptide sequence differs from the eight tetrapeptides used to generate the antibodies. These antibodies have the potential to identify novel neo-epitopes produced by caspase cleavage and so can be used to identify pathway-specific caspase cleavage events in a specific cell type. Additionally this methodology may be applied to generate antibodies against products of other proteases, which have a well-defined and non-promiscuous cleavage activity. Cell Death and Disease (2011) 2, e205; doi:10.1038/cddis.2011.91; published online 1 September 2011
引用
收藏
页码:e205 / e205
页数:8
相关论文
共 21 条
[1]
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective [J].
Amur, Shashi ;
Frueh, Felix W. ;
Lesko, Lawrence J. ;
Huang, Shiew-Mei .
BIOMARKERS IN MEDICINE, 2008, 2 (03) :305-311
[2]
Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor [J].
Bianchi, E ;
Liang, XP ;
Ingallinella, P ;
Finotto, M ;
Chastain, MA ;
Fan, J ;
Fu, TM ;
Song, HC ;
Horton, MS ;
Freed, DC ;
Manger, W ;
Wen, E ;
Shi, L ;
Ionescu, R ;
Price, C ;
Wenger, M ;
Emini, EA ;
Cortese, R ;
Ciliberto, G ;
Shiver, JW ;
Pessi, A .
JOURNAL OF VIROLOGY, 2005, 79 (12) :7380-7388
[3]
Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas [J].
Brandt, Doreen ;
Volkmann, Xandra ;
Anstaett, Matthias ;
Laenger, Florian ;
Manns, Michael P. ;
Schulze-Osthoff, Klaus ;
Bantel, Heike .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (08) :1464-1473
[4]
Antibodies against c-Jun N-terminal peptide cross-react with neo-epitopes emerging after caspase-mediated proteolysis during apoptosis [J].
Casas, C ;
Ribera, J ;
Esquerda, JE .
JOURNAL OF NEUROCHEMISTRY, 2001, 77 (03) :904-915
[5]
Global mapping of the topography and magnitude of proteolytic events in apoptosis [J].
Dix, Melissa M. ;
Simon, Gabriel M. ;
Cravatt, Benjamin F. .
CELL, 2008, 134 (04) :679-691
[6]
DONNELLY JJ, 1990, J IMMUNOL, V145, P3071
[7]
Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys [J].
Fan, JA ;
Liang, XP ;
Horton, MS ;
Perry, HC ;
Citron, MP ;
Heidecker, GJ ;
Fu, TM ;
Joyce, J ;
Przysiecki, CT ;
Keller, PM ;
Garsky, VM ;
Ionescu, R ;
Rippeon, Y ;
Shi, L ;
Chastain, MA ;
Condra, JH ;
Davies, ME ;
Liao, J ;
Emini, EA ;
Shiver, JW .
VACCINE, 2004, 22 (23-24) :2993-3003
[8]
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy [J].
Fulda, S. ;
Debatin, K. -M .
ONCOGENE, 2006, 25 (34) :4798-4811
[9]
Exploiting Apoptosis Pathways for the Treatment of Pediatric Cancers [J].
Fulda, Simone .
PEDIATRIC BLOOD & CANCER, 2009, 53 (04) :533-536
[10]
Serum efficacy biomarkers for oncology [J].
Linder, Stig ;
Alaiya, Ayodele .
BIOMARKERS IN MEDICINE, 2009, 3 (01) :47-54